Ultimovacs - Two for two in melanoma Phase I trial
Ultimovacs has shared an encouraging update from its Phase I trial (UV1-103) assessing UV1 in combination with pembrolizumab for the treatment of malignant melanoma. The latest data show that 11 out of 16 patients who agreed to long-term monitoring from cohort 1 were confirmed alive at the four-year follow-up point, corresponding to an overall survival (OS) rate of 69%. This demonstrates a durable benefit of Ultimovac’s lead cancer vaccine, in our view, indicating no confirmed patient deaths since the three-year follow-up point for this cohort. Four-year survival data in both cohorts are anticipated in Q224. We note that the UV1-103 study is treating the same patient population as the Phase II INITIUM trial, for which top-line results are expected in H124. We believe that the readouts for UV1 as a potential treatment for malignant melanoma in this period could represent a major catalyst for investor attention.Ultimovacs ASA Formerly known as Ultimovacs AS. Ultimovacs ASA, formerly Ultimovacs AS, is a Norway-based pharmaceutical company developing immunotherapies against cancer. The Company's lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase. UV1 is being developed as a therapeutic cancer vaccine which may serve as a platform for use in combination with other immuno-oncology drugs which require an ongoing T cell response for their mode of action. The Company is performing a broad clinical development program with clinical trials in Europe and the USA.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.